A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China (ADMIRE)

A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Study Overview

• Status: Active, not recruiting
• Conditions: Plaque Psoriasis
• Intervention / Treatment: Drug: Deucravacitinib

• Study Type: Observational
• Enrollment (Actual): 153

Contacts and Locations

Study Locations

• China
  • Beijing, China, 102218
    • Local Institution - 0003
  • Guangdong
    • Guangzhou, Guangdong, China, 510091
      • Local Institution - 0001
  • Hebei
    • Handan, Hebei, China, 056029
      • Local Institution - 0002
  • Liaoning
    • Dalian, Liaoning, China, 116021
      • Local Institution - 0005
  • Shanghai Municipality
    • Shanghai, Shanghai Municipality, China, 200080
      • Local Institution - 0004

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult participants aged ≥ 18 years who have been diagnosed with moderate plaque psoriasis who are starting deucravacitinib treatment in China

Description

Inclusion Criteria:

• Participant aged 18 years or older
• Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
• Participant newly initiated deucravacitinib according to the label
• Provided written informed consent to participate in the study

Exclusion Criteria:

• Participating in or planning to participate in an interventional clinical trial
• Concomitant use of other systemic treatments for psoriasis at baseline
• Prior treatment of deucravacitinib

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Participants treated with deucravacitinib; Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label	Drug: Deucravacitinib; As per product label

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score	Week 16
Participant psoriasis Body Surface Area (BSA) involvement	Week 16
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3	Week 16

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response	Baseline and Weeks 4, 12, 24, 36, and 52
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5	Baseline and Weeks 4, 12, 24, 36, and 52
Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline	Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in Body Surface Area (BSA) involvement from baseline to follow-up	Weeks 4, 12, 24, 36, and 52
Static Physician's Global Assessment (sPGA) 0/1 response at follow-up	Weeks 4, 12, 24, 36, and 52
Participants change in Static Physician's Global Assessment (sPGA) score from baseline	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score	Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in participant Dermatology Life Quality Index (DLQI) score from baseline	Baseline and Weeks 4, 12, 16, 24, 36, and 52

Collaborators and Investigators

• Sponsor: Bristol-Myers Squibb
• Investigators: Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

Helpful Links

• BMS Clinical Trial Information
• FDA Safety Alerts and Recalls

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2025
• Primary Completion (Estimated): March 11, 2027
• Study Completion (Estimated): March 11, 2027

Study Registration Dates

• First Submitted: July 16, 2024
• First Submitted That Met QC Criteria: July 16, 2024
• First Posted (Actual): July 22, 2024

Study Record Updates

• Last Update Posted (Actual): April 15, 2026
• Last Update Submitted That Met QC Criteria: April 14, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Plaque psoriasis
• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Psoriasis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Dermatologic Agents; Protein Kinase Inhibitors; deucravacitinib
• Other Study ID Numbers: IM011-1180

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No